Targeted Therapy for High-Risk Myeloid Malignancies: Aza+/-Ven in Older AML Disease, Aza/Dec for MDS, Ven+Aza in Treatment-Naïve MDS, Ena/Ivo for IDH-Mutated MPN

84 views
February 15, 2021
0 Comments
Login to view comments. Click here to Login
UChicago Genetics in Clinical Cancer Care